Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Sze, Chun I ^a   Su, Wan Pei ^b   Chiang, Ming Fu ^c,d   Lu, Chen Yu ^b   Chen, Yu An ^b   Chang, Nan Shan ^b,e,f  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Cancer stem cell; Extracellular matrix; Glioblastoma multiforme; Resistance mechanisms; Temozolomide; TIAF1 expression

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED ANTIAPOPTOTIC FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN HERNIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CELL DIFFERENTIATION; EPIGENETIC REPRESSION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 84890710269     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00059     Document Type: Short Survey

References (52)

1. Barth, R. F., Vicente, M. G., Harling, O. K., Kiger, W. S. III, Riley, K. J., Binns, P. J., et al. (2012). Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 7, 146.
2. Batchelor, T. T., Sorensen, A. G., Di Tomaso, E., Zhang, W. T., Duda, D. G., Cohen, K. S., et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.
3. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603.
4. Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., et al. (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752. doi:10.1371/journal.pone.0007752
5. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
6. Camara-Quintana, J. Q., Nitta, R. T., and Li, G. (2012). Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg. Clin. N. Am. 23, 237-246, viii.
7. Cancer Genome Atlas Research, N. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
8. Carén, H., Pollard, S. M., and Beck, S. (2012). The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma. Mol. Aspects Med. doi:10.1016/j.mam.2012.06.007. [Epub ahead of print].
9. Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
10. Chang, J. Y., Chiang, M. F., Lin, S. R., Lee, M. H., He, H., Chou, P. Y., et al. (2012). TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis. 3, e302.
11. Chang, N. S., Mattison, J., Cao, H., Pratt, N., Zhao, Y., and Lee, C. (1998). Cloning and characterization of a novel transforming growth factor-beta1-induced TIAF1 protein that inhibits tumor necrosis factor cytotoxicity. Biochem. Biophys. Res. Commun. 253, 743-749.
12. Chi, A. S., Batchelor, T. T., Kwak, E. L., Clark, J. W., Wang, D. L., Wilner, K. D., et al. (2012). Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J. Clin. Oncol. 30, e30-e33.
13. De Wever, O., Pauwels, P., De Craene, B., Sabbah, M., Emami, S., Redeuilh, G., et al. (2008). Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell Biol. 130, 481-494.
14. De Witt Hamer, P. C. (2010). Small molecule kinase inhibitors in glioblastoma: A systematic review of clinical studies. Neuro-oncology 12, 304-316.
15. Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317-1324.
16. Dietrich, J., Diamond, E. L., and Kesari, S. (2010). Glioma stem cell signaling: Therapeutic opportunities and challenges. Expert Rev. Anticancer Ther. 10, 709-722.
17. Fenton, T. R., Nathanson, D., Ponte De Albuquerque, C., Kuga, D., Iwanami, A., Dang, J., et al. (2012). Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. U.S.A. 109, 14164-14169.
18. Foltz, G., Yoon, J. G., Lee, H., Ma, L., Tian, Q., and Hood, L. (2010). Epigenetic regulation of Wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer 1, 81-90.
19. Gan, Q., Yoshida, T., McDonald, O. G., and Owens, G. K. (2007). Concise review: Epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 25, 2-9.
20. Halatsch, M. E., Schmidt, U., Behnke-Mursch, J., Unterberg, A., and Wirtz, C. R. (2006). Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. 32, 74-89.
21. Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., et al. (2010). Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 118, 585-594.
22. Huse, J. T., and Holland, E. C. (2010). Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319-331.
23. Jin, X., Jeon, H. Y., Joo, K. M., Kim, J. K., Jin, J., Kim, S. H., et al. (2011). Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 71, 3066-3075.
24. Kalluri, R., and Neilson, E. G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784.
25. Khera, S., and Chang, N. S. (2003). TIAF1 participates in the transforming growth factor beta1-mediated growth regulation. Ann. N. Y. Acad. Sci. 995, 11-21.
26. Kim, K. H., Seol, H. J., Kim, E. H., Rheey, J., Jin, H. J., Lee, Y., et al. (2013). Wnt/ß-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro-oncology 15, 161-171.
27. Lee, M. H., Lin, S. R., Chang, J. Y., Schultz, L., Heath, J., Hsu, L. J., et al. (2010). TGF-ß induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid ß plaques in Alzheimer's disease. Cell Death Dis. 1, e110.
28. Lukas, R. V., Boire, A., and Nicholas, M. K. (2009). Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther. 2, 115-133.
29. Moon, Y. W., Weil, R. J., Pack, S. D., Park, W. S., Pak, E., Pham, T., et al. (2000). Missense mutation of the MET gene detected in human glioma. Mod. Pathol. 13, 973-977.
30. Nduom, E. K., Bouras, A., Kaluzova, M., and Hadjipanayis, C. G. (2012). Nanotechnology applications for glioblastoma. Neurosurg. Clin. N. Am. 23, 439-449.
31. Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522.
32. Ohgaki, H., and Kleihues, P. (2007). Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445-1453.
33. Omuro, A. M., Faivre, S., and Raymond, E. (2007). Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6, 1909-1919.
34. Pala, A., Karpel-Massler, G., Kast, R. E., Wirtz, C. R., and Halatsch, M. C. (2012). Epidermal to mesenchymal transition and failure of EGFR-targeted therapy in glioblastoma. Cancers 4, 523-530.
35. Paulsson, J., Lindh, M. B., Jarvius, M., Puputti, M., Nister, M., Nupponen, N. N., et al. (2011). Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int. J. Cancer 128, 1981-1988.
36. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
37. Singh, M. M., Manton, C. A., Bhat, K. P., Tsai, W. W., Aldape, K., Barton, M. C., et al. (2011). Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-oncology 13, 894-903.
38. Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290.
39. Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.
40. Szerlip, N. J., Pedraza, A., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., et al. (2012). Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. U.S.A. 109, 3041-3046.
41. Tafani, M., Di Vito, M., Frati, A., Pellegrini, L., De Santis, E., Sette, G., et al. (2011). Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflammation 8, 32.
42. Takagaki, M., Powell, W., Sood, A., Spielvogel, B. F., Hosmane, N. S., Kirihata, M., et al. (2001). Boronated dipeptide borotrimethylglycylphenylalanine as a potential boron carrier in boron neutron capture therapy for malignant brain tumors. Radiat. Res. 156, 118-122.
43. Takano, S. (2012). Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 29, 73-86.
44. Tektonidis, M., Hatzikirou, H., Chauviere, A., Simon, M., Schaller, K., and Deutsch, A. (2011). Identification of intrinsic in vitro cellular mechanisms for glioma invasion. J. Theor. Biol. 287, 131-147.
45. Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483.
46. von Deimling, A., Korshunov, A., and Hartmann, C. (2011). The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 21, 74-87.
47. Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., et al. (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J. Clin. Oncol. 27, 5743-5750.
48. Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507.
49. Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874-5880.
50. Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.
51. Xu, J., Lamouille, S., and Derynck, R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19, 156-172.
52. Yilmaz, O. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482.